Avacta Completes Sale of Launch Diagnostics to Duomed Belgium

An update from Avacta Group plc ( (GB:AVCT) ) is now available.

Avacta Group plc has completed the sale of its largest diagnostics unit, Launch Diagnostics Holdings Limited, to Duomed Belgium NV, a subsidiary of Palex Healthcare Group S.L.U. This strategic move allows Avacta to focus on its core business of developing innovative cancer therapies, potentially strengthening its position in the life sciences industry and impacting stakeholders by streamlining operations and enhancing its market focus.

More about Avacta Group plc

Avacta Group plc is a clinical-stage life sciences company focused on developing next-generation peptide drug conjugates (PDC) that target anti-tumor payloads directly to tumors. Utilizing its proprietary pre|CISION® platform, Avacta aims to enhance the delivery and efficacy of cancer therapies by concentrating potent payloads in the tumor microenvironment while minimizing effects on healthy tissues.

YTD Price Performance: -25.50%

Average Trading Volume: 1,715,404

Technical Sentiment Signal: Buy

Current Market Cap: £138.9M

For an in-depth examination of AVCT stock, go to TipRanks’ Stock Analysis page.